Cart
sales@molnova.com
Magrolimab
CAS No. 2169232-81-7
Magrolimab( —— )
Catalog No. M34758 CAS No. 2169232-81-7
Magrolimab (Hu5F9-G4) is a humanized anti-CD47 IgG4 monoclonal antibody that exhibits antitumor activity by blocking CD47 and binding primarily to the N-terminal pyroglutamate of CD47. It can be used in combination with other compounds for the treatment of recurrent myeloma.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 455 | Get Quote |
|
| 10MG | 708 | Get Quote |
|
| 25MG | 1064 | Get Quote |
|
| 50MG | 1386 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameMagrolimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionMagrolimab (Hu5F9-G4) is a humanized anti-CD47 IgG4 monoclonal antibody that exhibits antitumor activity by blocking CD47 and binding primarily to the N-terminal pyroglutamate of CD47. It can be used in combination with other compounds for the treatment of recurrent myeloma.
-
DescriptionMagrolimab (Hu5F9-G4) is a first-in-class humanized anti-CD47 IgG4 antibody with an anti-tumor activity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2169232-81-7
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Caner Saygin, et al. Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021 Jul;48:100791.?
molnova catalog
related products
-
β-cyano-L-Alanine
β-cyano-L-Alanine is a nitrile of widespread occurrence in higher plants.
-
Acacetin 7-[rhamnosy...
The fruits of Fortunella japonica.
-
B I09
B I09, an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells.
